New York, Aug. 17, 2023 (GLOBE NEWSWIRE) -- The global revenue from the perfusion bioreactors market is estimated to reach US$ 345.6 Million in 2022, with the global market growing at a 7.2% CAGR to ...

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Perfusion Bioreactors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product ...

Sartorius Stedim Biotech (SSB) said today it will integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion ...

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry today announced the launch of the ambr ® 250 high throughput (ht) perfusion, a new automated ...

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, ...

The biopharmaceutical and biotech industries face mounting challenges in regulated environments, including rising drug development costs, strict regulatory demands, and the need for scalable, ...

Recent Survey Finds Commercial-Stage Use of Disposables Continuing on Upward Trajectory Bioreactors are constantly evolving, with improvements being introduced rapidly. To assess how the industry will ...

Process intensification has reduced the cost of mAb manufacturing, but tweaks across bioproduction will be needed to reduce ...

BANGALORE, India, Feb. 19, 2024 /PRNewswire/ -- Perfusion Bioreactor Market is Segmented by Type (Small Scale (Less Than 100 Liters), Mid-Scale (100 Liters to 1,000 Liters), Large Scale (More Than ...

A collaboration integrates Sartorius Stedim Biotech’s BIOSTAT STR bioreactors and Repligen’s XCell ATF cell-retention control technology to create simplified, scalable equipment for intensified cell ...